Pfizer
3 articles
Industry NewsPfizer / Blackstone Life SciencesBioPharma Dive
Blackstone commits up to $1.5B to fund Pfizer’s monthly obesity shot through Phase 3
- Blackstone Life Sciences will put up to $1.5B, phased through 2028, into Pfizer’s Phase 3 program for berobenatide, a potentially once-monthly GLP-1 injectable that came with the roughly $10B Metsera acquisition.
- The money backs as many as 10 pivotal studies; Pfizer owes Blackstone milestones if the drug is approved as a monthly single agent and hits sales goals, paid as multi-year distributions.
- Pfizer may run head-to-head trials against Zepbound and Wegovy, not just placebo-controlled studies.
This is Pfizer syndicating the risk of an expensive catch-up bet: it paid up to win Metsera, and now shares the Phase 3 bill so the cash can stay on Eliquis- and Ibrance-patent-cliff priorities. Blackstone’s return rides on approval and sales, so the structure only works if monthly dosing is a real differentiator against Lilly and Novo, who already have oral pills out. The open question is whether head-to-head data arrive early enough to matter commercially.
Industry NewsPfizerEndpoints News
Pfizer details mixed Phase 3 data for Lyme disease vaccine
- Pfizer and Valneva presented fuller results from their Phase 3 Lyme disease vaccine study on Thursday, with outcomes described as mixed.
- One of the two analyses reportedly came close to, but fell short of, its target.
- The vaccine's commercial prospects are described as uncertain pending the next steps.
A near-miss on one of two analyses is a weak footing for a first-in-class Lyme vaccine, and it hands regulators room to ask hard questions. Pfizer carries the commercial risk alongside Valneva, so the filing path and label breadth now matter more than the headline efficacy. Details are thin, so treat any launch timing as unsettled.
Industry NewsPfizer / Enodia TherapeuticsFierce Biotech
Pfizer partners with Enodia on Sec61 inhibitors in a deal worth over $500M
- Enodia will use its platform to find and develop Sec61 inhibitors against several targets; Pfizer takes on clinical, manufacturing, regulatory and commercial work.
- The upfront is undisclosed; R&D and sales milestones could push the total above $500M, with tiered royalties on top.
- It follows Lilly's deal with Gate Bioscience in the same Sec61 space, reportedly worth about $870M.
Sec61 is a hard target: it is a core translocon, and the chemistry has to block only disease-linked proteins without general toxicity. Two big pharmas moving within a week suggests selectivity data are persuasive behind closed doors, but the undisclosed upfront and targets mean the real signal is still thin. Watch which client proteins each company is going after.